EOLS Stock Analysis
EO
Uncovered
Evolus Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 215 full-time employees. The company went IPO on 2018-02-08. Its first commercial product is Jeuveau, which is a 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. Jeuveau is manufactured using Hi-Pure technology. The firm commercially launched Jeuveau in the United States. The firm manufactures both Jeuveau and BOTOX. BOTOX (onabotulinumtoxinA) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.